Cefalexin was developed in 1967.[8][9][10] It was first marketed in 1969 and 1970 under the names Keflex and Ceporex, among others.[11][12] It is available as a generic medication.[4][13] It is on the World Health Organization's List of Essential Medicines.[14] In 2021, it was the 96th most commonly prescribed medication in the United States, with more than 7million prescriptions.[15][16] In Canada, it was the fifth most common antibiotic used in 2013.[17] In Australia, it is one of the top 15 most prescribed medications.[18]
^Cite error: The named reference Lexylan PI was invoked but never defined (see the help page).
^McEvoy, G.K. (ed.). American Hospital Formulary Service — Drug Information 95. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1995 (Plus Supplements 1995)., p. 166
^ abcdefghijklmno"Cephalexin". The American Society of Health-System Pharmacists. Archived from the original on 1 May 2014. Retrieved 21 April 2014.
^Brunton LL (2011). "Chapter 53: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics". Goodman & Gilman's pharmacological basis of therapeutics (12th ed.). New York: McGraw-Hill. ISBN978-0071624428.
^US patent 3275626, Morin RB, Jackson BG, "Penicillin conversion via sulfoxide", published 1966-09-27, issued 1966-09-27, assigned to Eli Lilly and Co"Espacenet - Bibliographic data". Archived from the original on 25 September 2022. Retrieved 3 March 2020.
^US patent 3507861, Morin RB, Jackson BG, "Certain 3-methyl-cephalosporin compounds", published 1970-04-21, issued 1970-04-21, assigned to Eli Lilly and Co"Espacenet - Bibliographic data". Archived from the original on 25 September 2022. Retrieved 3 March 2020.
^McPherson EM (2007). "Cefalexin". Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier. p. 915. ISBN9780815518563. Archived from the original on 8 September 2017.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.